Summary

Market Summary:
As per Market Research Future analysis, the necrotising enterocolitis market size was estimated at 163.32 USD Million in 2024. The necrotising enterocolitis market is projected to grow from 172.3 USD Million in 2025 to 294.36 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5% during the forecast period 2025 - 2035

Market Drivers:
Japan's increasing healthcare expenditure is a significant driver for the necrotising enterocolitis market. The government has been investing heavily in healthcare infrastructure, with spending projected to reach approximately $500 billion by 2026. This investment is likely to enhance the availability of advanced medical treatments and facilities for neonatal care, including those addressing necrotising enterocolitis. As healthcare budgets expand, hospitals are better equipped to implement comprehensive care protocols for at-risk infants. This trend may lead to improved outcomes and a higher demand for specialized treatments within the necrotising enterocolitis market. Additionally, increased funding for research and development in this area could foster innovation, further stimulating market growth in Japan. The rising incidence of premature births in Japan is a critical driver for the necrotising enterocolitis market. Statistics indicate that approximately 8% of all births in Japan are preterm, which significantly heightens the risk of developing necrotising enterocolitis. This condition predominantly affects infants born before 32 weeks of gestation.

Market Segment Analysis:
Japan Necrotizing Enterocolitis Market Segment Insights Necrotizing Enterocolitis Market End-User Insights The Japan Necrotizing Enterocolitis Market has shown significant segmentation toward various End-User categories, which play a crucial role in the diagnosis and treatment of this condition. Among these categories, hospitals are major players, equipped with specialized neonatology units and comprehensive care for infants diagnosed with necrotizing enterocolitis. Their capability to provide multi-disciplinary approaches makes them essential in managing both patient care and conducting research to further understand this serious condition. Surgical and ablation centers also represent a vital segment; they focus on advanced interventions and management techniques for severe cases, ensuring appropriate care for those requiring immediate attention. Necrotizing Enterocolitis Market Treatment Insights The Japan Necrotizing Enterocolitis Market treatment segment is integral to managing this serious gastrointestinal condition prevalent in neonates.

Regional Analysis:
The necrotising enterocolitis market in Japan is currently undergoing significant developments. This condition, primarily affecting premature infants, has garnered increased attention from healthcare providers and researchers alike. The rising incidence of this serious gastrointestinal disease has prompted a surge in demand for effective treatment options and preventive measures. As a result, various stakeholders, including pharmaceutical companies and healthcare institutions, are investing in research and development to enhance therapeutic strategies. Furthermore, the growing awareness of necrotising enterocolitis among healthcare professionals is likely to drive advancements in clinical practices and patient management. In addition, the regulatory landscape in Japan appears to be evolving, with authorities focusing on improving the safety and efficacy of treatments available for necrotising enterocolitis.

Major Players:
The following companies are key participants in the Japan Necrotising Enterocolitis Market, playing a crucial role in market development through technological innovation, strategic partnerships, and competitive product offerings.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
EXECUTIVE SUMMARY
Market Overview
Key Findings
Market Segmentation
Competitive Landscape
Challenges and Opportunities
Future Outlook

2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
MARKET INTRODUCTION
Definition
Scope of the study
Research Objective
Assumption
Limitations
RESEARCH METHODOLOGY
Overview
Data Mining
Secondary Research
Primary Research
Primary Interviews and Information Gathering Process
Breakdown of Primary Respondents
Forecasting Model
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Data Triangulation
Validation

3 SECTION III: QUALITATIVE ANALYSIS
MARKET DYNAMICS
Overview
Drivers
Restraints
Opportunities
MARKET FACTOR ANALYSIS
Value chain Analysis
Porter's Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Intensity of Rivalry
COVID-19 Impact Analysis
Market Impact Analysis
Regional Impact
Opportunity and Threat Analysis

4 SECTION IV: QUANTITATIVE ANALYSIS
Healthcare
Market Segmentation
Healthcare By Indication (USD Billion, 2025-2035)Premature Infants
Full-Term Infants
Neonates
Healthcare By Treatment Type (USD Billion, 2025-2035)Surgical Intervention
Medical Management
Nutritional Support
Healthcare
Japan By End User (USD Billion, 2025-2035)Hospitals
Specialized Clinics
Home Care Settings
Healthcare By Diagnosis Method (USD Billion, 2025-2035)Clinical Assessment
Imaging Techniques
Laboratory Tests SECTION V: COMPETITIVE ANALYSIS
Competitive Landscape
Overview
Competitive Analysis
Market share Analysis
Major Growth Strategy in the necrotising enterocolitis market
Competitive Benchmarking
Leading Players in Terms of Number of Developments in the necrotising enterocolitis market
Key developments and growth strategies
New Product Launch/Service Deployment
Merger & Acquisitions
Joint Ventures
Major Players Financial Matrix
Sales and Operating Income
Major Players R&D Expenditure. 2023
Company Profiles
Takeda Pharmaceutical Company
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Astellas Pharma Inc.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Mitsubishi Tanabe Pharma Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Daiichi Sanky
Company, Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Otsuka Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Chugai Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Eisai Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Kyowa Kirin Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Appendix
References
Related Reports

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
LIST OF ASSUMPTIONS
Japan NECROTISING ENTEROCOLITIS MARKET SIZE ESTIMATES; FORECAST
TABLE 1 BY END-USER, 2026-2035 (USD Million)
TABLE 2 BY END-USER, 2026-2035 (USD Million)
TABLE 3 BY TREATMENT, 2026-2035 (USD Million)
TABLE 4 BY TREATMENT, 2026-2035 (USD Million)
TABLE 5 BY DISTRIBUTION, 2026-2035 (USD Million)
TABLE 6 BY DISTRIBUTION, 2026-2035 (USD Million)
PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
ACQUISITION/PARTNERSHIP

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 JAPAN NECROTISING ENTEROCOLITIS MARKET ANALYSIS BY END-USER
FIGURE 3 JAPAN NECROTISING ENTEROCOLITIS MARKET ANALYSIS BY TREATMENT
FIGURE 4 JAPAN NECROTISING ENTEROCOLITIS MARKET ANALYSIS BY DISTRIBUTION
FIGURE 5 KEY BUYING CRITERIA OF NECROTISING ENTEROCOLITIS MARKET
FIGURE 6 RESEARCH PROCESS OF MRFR
FIGURE 7 DRO ANALYSIS OF JAPAN NECROTISING ENTEROCOLITIS MARKET
FIGURE 8 DRIVERS IMPACT ANALYSIS: JAPAN NECROTISING ENTEROCOLITIS MARKET
FIGURE 9 RESTRAINTS IMPACT ANALYSIS: JAPAN NECROTISING ENTEROCOLITIS MARKET
FIGURE 10 SUPPLY / VALUE CHAIN: JAPAN NECROTISING ENTEROCOLITIS MARKET
FIGURE 11 JAPAN NECROTISING ENTEROCOLITIS MARKET, BY END-USER, 2024 (% SHARE)
FIGURE 12 JAPAN NECROTISING ENTEROCOLITIS MARKET, BY END-USER, 2024 TO 2035 (USD Million)
FIGURE 13 JAPAN NECROTISING ENTEROCOLITIS MARKET, BY TREATMENT, 2024 (% SHARE)
FIGURE 14 JAPAN NECROTISING ENTEROCOLITIS MARKET, BY TREATMENT, 2024 TO 2035 (USD Million)
FIGURE 15 JAPAN NECROTISING ENTEROCOLITIS MARKET, BY DISTRIBUTION, 2024 (% SHARE)
FIGURE 16 JAPAN NECROTISING ENTEROCOLITIS MARKET, BY DISTRIBUTION, 2024 TO 2035 (USD Million)
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS